



NEW AND OLD ASSUMPTIONS ON LUNG CANCER IN PEOPLE LIVING WITH HIV

F. D'ALEO¹, B.A.V. CAMA¹, I.A. PAOLUCCI¹, E. VENANZI RULLO¹,
F. CONDORELLI², A. FACCIOLÀ¹, R. DI FRANZIA³, A. SAVASTA¹, M. R. PINZONE⁴,
I. PICERNO⁵, G. VISALLI⁵, G. NUNNARI¹, G. F. PELLICANÒ⁶, M. CECCARELLI¹

¹Department of Clinical and Experimental Medicine, Unit of Infectious Diseases, University of Messina, Messina, Italy

²Department of Pharmacological Sciences, Università del Piemonte Orientale "A. Avogadro", Novara, Italy

³Department of Medical Oncology A, National Cancer Institute of Aviano, Aviano, Italy

⁴Department of Pathology and Laboratory Medicine, School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

⁵Department of Biomedical and Dental Sciences and Morpho Functional Imaging, University of Messina, Messina, Italy

⁶Department of Human Pathology of the Adult and the Developmental Age "G. Barresi", Unit of Infectious Diseases, University of Messina, Messina, Italy

Francesco D'Aleo and Battistina Antonia Valeria Cama equally contributed to the realization of this work

Abstract – People living with HIV nowadays have an average life-length similar to the general population and new pathologies, such as lung cancer, emerged. The likelihood of developing lung cancer in HIV-infected people is related to the increase of the mean age, male sex, smoke, persistent lung inflammation, and new studies are being conducted to find new soluble markers which could lead to an early diagnosis of lung cancer. Moreover, treatment opportunities are being enriched with new biological medicine, even though further studies are needed to determine if their use is safe in people living with HIV. The aim of this review is to identify key data and factors about lung cancer in HIV-infected patients.

KEYWORDS: Lung cancer, HIV, Screening, Therapy, Markers.

INTRODUCTION

The Acquired Immuno-Deficiency Syndrome (AIDS) outbreak started in 1981. HIV infected people, predominantly previously healthy young men, started to develop diseases considered to be limited to the immunocompromised patients. Acquiring the HIV infection lead to an extremely reduced life expectancy in those years. The introduction of Highly Active Anti-Retroviral Therapy (HAART) in 1996 completely changed this scenario. Nowadays, people living with HIV (PLWH) have an average life-length similar to the general population and new pathologies linked to adverse-effects of a

life-long therapy, aging and HIV-related persistent inflammation emerged, leading to new issues to deal with and hopefully resolve¹⁻²².

Infectious, inflammatory and neoplastic lung diseases have been a major co-morbidity in HIV-infected patients since the beginning of the HIV epidemic, because of the high prevalence of smokers within the HIV-positive population and the role played by viral and host factors. Lung cancer, the most common cancer in the world, heavily affects PLWH, representing today the leading cause of death in this population, having a three-fold higher incidence than general population with the worst prognosis^{1-3,21,23-26}.



Independent factors specifically associated with HIV infection, such as a direct oncogenic action, recurrent lung infections and immune depression, contribute to this increased risk; then, lung cancer is nowadays the most common non-AIDS defining cancer (NADC) in HIV patients^{23,25,27}.

In this report, we review the diagnostic and therapeutic management of lung cancer in HIV infected patients.

RISK FACTORS AND PATHOGENESIS

The likelihood of developing lung cancer is related to the increase of the mean age in PLWH²⁸⁻³⁰. After the introduction of HAART, life expectancy of PLWH has considerably increased, leading to a directly proportional rise in the prevalence of lung cancer³¹⁻³⁵. Male sex is related with the highest risk, probably because of the higher prevalence of HIV-infection and smoke in men than women^{36,37}.

Smoking is the most important risk factor. HIV-infected smokers seem to develop lung cancer at a younger age than non-smokers. Bonnet et al³⁸ claim that 90% of the PLWH died from lung cancer during a period going from 2000 to 2005. Smoking history is crucial for the development of lung cancer, seen that a 20 to 35 pack-year smoking history has been associated with the development of lung cancer in PLWH³⁹. A number ≥ 30 of pack years is one of the parameters used for determining the need of lung cancer screening in PLWH, as suggested in the 2017 Italian's HIV-guidelines⁴⁰.

Persistent lung inflammation due to recurrent infections can only partially explain the increased risk of developing lung cancer in PLWH, and Shebl et al⁴¹ demonstrated that pneumonitis, but not tuberculosis or PCP, is associated with an increase in lung cancer incidence. However, this association was not confirmed when adjusted for smoking.

As reported by Sigel et al⁴², Drummond et al⁴³ and Crothers et al⁴⁴, Chronic Obstructive Pulmonary Disorders (COPDs) are major risk factors for developing a lung cancer in PLWH who, in addition, have a higher risk of developing COPD because of an increased lung inflammation, in a vicious cycle that seems to have no escape.

HIV infection also brings with itself a series of risk factors related to immunosuppression, inflammation, viral oncogenesis, and HAART⁴².

A low CD4+ T-cell count is reported to be associated to an increased incidence of lung cancer incidence in more than one longitudinal study, which highlighted that PLWH who do not recover a CD4+ count of at least 500/ μ L during their life are at increased risk of developing it^{42,45}. Moreover, Borges et al⁴⁶ highlighted how, before the

diagnosis of lung cancer, pro-inflammatory cytokines, such as IL-6, can be found to be elevated.

HIV could also have a direct oncogenic action in the development of lung cancer. Cribbs et al⁴⁷ demonstrated that a wide percentage of a small cohort of non-smoker PLWH with a suppressed serological viral load, had detectable pro-viral DNA in alveolar macrophages.

Further studies are needed to increase our knowledge about lung cancer pathogenesis in PLWH, in order to prevent its development, if possible.

DIAGNOSIS

NON-INVASIVE SCREENING AND DIAGNOSTIC TECHNIQUES

Patients are mostly asymptomatic at early stages or they can have non-specific symptoms. Patients diagnosed at Stage I are commonly curable and have a 5-year survival rate of 50-80%^{28,30,48,49}.

Unfortunately, in PLWH the diagnosis is often delayed exactly because of the lack of specific symptoms. As a matter of fact, the most commonly reported symptoms in HIV patients with lung cancer are: cough, weight loss, dyspnea, night sweats, chest pain, and anorexia⁵⁰⁻⁵³.

Screening of high-risk individuals is necessary to find the disease at an early stage and improve the patients' survival. Moreover, it is fundamental in offering a better opportunity for treatment. Italian Guidelines for the management of HIV infection suggest that PLWH who smoke more than 30 pack of cigarettes per year should undergo a low-dose Computed Tomography (CT) scan⁴⁰.

However, asymptomatic PLWH have a high prevalence of pulmonary nodules unrelated to lung cancer. Therefore, in 2004 the US Preventive Service Task Force concluded that a screening program of asymptomatic people for lung cancer was not cost-effective⁵⁴⁻⁵⁶ and in 2017 the European AIDS Clinical Society (EACS) still chose to not include lung cancer in their guidelines for the management of patients with HIV infection⁵⁷.

In the suspect of lung cancer, the first examination performed is a chest x-ray. A wide spectrum of radiological signs can suggest the presence of a primary lung tumor, making a Computed Tomography (CT) necessary to confirm the diagnosis.

Recently, the emergence of combined PET/CT imaging has greatly aided the investigation of lung cancer; this technique has been shown to be an accurate tool for the work-up of solitary pulmonary nodules and improves the detection of metastatic disease⁵⁸⁻⁶¹.

An accurate assessment of the disease extent is important to discern the best management: surgery, chemotherapy, radiotherapy or any combination of them⁶²⁻⁶⁹.

NEW MOLECULAR MARKERS

Many authors investigated about noninvasive and molecular methods to detect and monitor tumors. Micro-RNAs, a group of endogenous and non-coding RNAs working as post-transcriptional regulators of gene expression by affecting the stability and translation of mRNAs, are currently under investigation for being involved in development, invasion and metastasis of tumors, playing a role as both tumor suppressors and oncogenes. Wang et al⁷⁰, starting from an observation of Zhao et al⁷¹, showed that the serum miR-411 levels increase in patients with NSCLCs and are significantly associated with TNM stage, differentiation degree and survival. Therefore, it can be concluded that miR-411 works as a tumor promoter in lung cancer, and particularly in NSCLC. This result may have clinical potentials and this marker could be used as a non-invasive diagnostic/prognostic biomarker.

Long noncoding RNAs, poorly conserved and not translated into proteins transcripts, are also currently being studied in search for any association with the development of neoplasms.

Speaking of NSCLCs, several studies observed that LINC00152 was upregulated in both NSCLC tissues and plasma samples of patients affected by lung cancer. Moreover, levels of plasma/serum LINC0052 in patients affected by NSCLC are significantly higher than those expressed in patients affected by benign lung diseases or healthy controls⁷²⁻⁷⁵.

Two other lncRNAs (DKFZP434 L187 and LOC285548) are correlated with lung adenocarcinoma and may have prognostic value for the survival⁷².

Aldehyde dehydrogenase 1 family, member A1 (ALDH1A1) is highly expressed in non-small-cell lung cancer and studies demonstrated that ALDH1A1 correlated with carcinogenesis and progression of NSCLCs⁷⁶⁻⁸⁰. Further studies are required to establish the ability of these biomarkers to discriminate between inflammation during lung diseases and cancer. Moreover, studies including PLWH are needed to determine if these soluble biomarkers are equally related to lung cancer in this population.

CLASSIFICATION OF LUNG CANCER

In 2015, the World Health Organization (WHO) published a new textbook of lung cancer classification with a number of important changes, compared to previous editions⁸¹.

Unrepressed cell growth, tissue invasion and the development of metastasis due to anomalous expression of oncogenes are distinguishing signs of a cancer cell. In PLWH the risk to develop a neoplasm is increased because of the role played by HIV protein Tat in regulating cell prolif-

eration^{22,82,83}. However, as previously discussed, studies failed in finding a link between HIV viral load and lung cancer⁸⁴⁻⁸⁶.

There are two major types of lung cancer classified as non-small cell lung cancer (NSCLC) and small cell lung cancer. The new WHO classification includes types and subtypes of epithelial tumors, such as: adenocarcinoma (subtypes acinar, papillary, micropapillary); squamous cell carcinoma (types: keratinizing squamous cell carcinoma, non-keratinizing squamous cell carcinoma, basaloid); neuroendocrine tumors (small cell carcinoma and large cell carcinoma). The non-epithelial tumors are included in specific tables⁸⁷⁻⁸⁹. The extension of a tumor is definite by the TNM classification⁹⁰⁻⁹³. The most frequently encountered cancers in HIV-patients are NSCLCH. The most common histologic type of lung cancer is adenocarcinoma (67%), followed by squamous cell carcinoma, large cell carcinoma and bronco-alveolar carcinoma; small cell lung cancer comprises a small group with unidentified subtypes^{3,23,94-97}.

THERAPIES

The first step to obtain a better outcome is a proper diagnosis with an accurate staging of the cancer and the application of the principles of personalized medicine. Surgery remains the treatment of choice and has an important role in definitive management of lung cancer^{98,99}. Early stages (I-II) are usually treated with surgery and evaluation of the lymph nodes. Darling et al¹⁰⁰ showed that, for patients treated with a resection of the tumor in an early stage, the disease-free rate at 5 years was 68%⁹³. Lobectomy is the current technique for lung cancer resection; in the case of small tumors, a sub-lobar resection removing a small portion of pulmonary tissue may be used¹⁰¹.

Advanced stages (III) of lung cancer need to be treated with combination therapies¹⁰². The use of chemotherapy or radiation before surgery (neoadjuvant therapy) may help the surgeon to remove the mass reducing its diameter. Evidence suggests that chemotherapy after surgery may help to prevent a relapse (adjuvant therapy)¹⁰³. Targeted treatments are a new option for the management of NSCLCs. Several monoclonal antibodies are currently used, like Erlotinib and Afatinib, inhibitors of the epithelial growth factor receptor of the tyrosine-kinase family¹⁰⁴⁻¹⁰⁶, or Crizotinib, an inhibitor of the anaplastic lymphoma kinase and the c-ros oncogene¹⁰⁷.

Immunotherapy is generally well-tolerated and has recently emerged as a new treatment possibility with significantly improved outcomes in patients affected by lung cancers.



Two different immune checkpoint inhibitors that target Programmed Cell Death 1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) have been discovered during the past years. These inhibitors seem to be effective even against metastatic NS-CLCs and play an inhibitory function on T-cells activation in peripheric tissues¹⁰⁸.

Several studies^{109,110} have been performed to define the interactions between HIV disease and immune checkpoint molecules. However, there is poor evidence that the immunotherapies can be used in patients with immune-compromised systems like HIV-positive people are. Marra et al¹¹¹, published a paper describing the use of immunotherapy in PLWH affected by melanoma. Furthermore, the American Cancer Association (ACA) suggests that patients with HIV should no longer be excluded from new therapies for cancer. Furthermore, a study by ACA highlighted how the PD-1 inhibitor pembrolizumab does not show significant risks for patients with HIV and cancer¹¹².

CONCLUSIONS

Lung cancer has a high incidence and mortality, independently from HIV serological status. Because of that, it is a major worldwide public health problem. Early diagnosis is crucial. Detection of the cancer in an early stage means that a patient's disease-free at 5 years survival is over 60%. Furthermore, when a lung cancer is detected at an early stage, a curative treatment such as surgery is possible. Whenever it is possible, advanced tumors must be treated with combined treatments of surgery, chemo and radiotherapy. A pharmacological approach in advanced stage cancers is possible with the new experimental drugs, but guidelines for the use of monoclonal antibodies in HIV-patients with lung cancer are needed.

CONFLICT OF INTERESTS

The Authors declare that they have no conflict of interests.

REFERENCES

1. MAHALE P, ENGELS EA, COGHILL AE, KAHN AR, SHIELS MS. Clin Infect Dis 2018 Jan 8. doi: 10.1093/cid/ciy012. [Epub ahead of print]. Clin Infect Dis 2018. doi: 10.1093/cid/ciy012
2. HERNANDEZ-RAMIREZ RU, SHIELS MS, DUBROW R, ENGELS EA. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. Lancet HIV 2017; 4: e495-e504. doi: 10.1016/S2352-3018(17)30125-X
3. KIDERLEN TR, SIEHL J, HENTRICH M. HIV-Associated Lung Cancer. Oncol Res Treat 2017; 40: 88-92. doi: 10.1159/000458442

4. VISALLI G, BERTUCCIO MP, CURRÒ M, PELLICANÒ G, STURNIOLO G, CARNEVALI A, SPATARO P, IENTILE R, PICERNO I, CAVALLARI V, PIEDIMONTE G. Bioenergetics of T cell activation and death in HIV type 1 infection. AIDS Research and Human Retroviruses 2012; 28: 1110-1118. doi: 10.1089/AID.2011.0197
5. GIUNTINI R, MARTINELLI C, RICCI E, VICHI F, GIANELLI E, MADEDDU G, ABELI C, PALVARINI L, PENCO G, MARCONI P, GROSSO C, PELLICANÒ G, BONFANTI P, QUIRINO T. Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study. HIV Med 2010; 11: 40-45. doi: 10.1111/j.1468-1293.2009.00740.x
6. CAPELLI A, MERAVIGLIA P, LANDONIO S, STERRANTINO G, DI BIAGIO A, CAPUTO LO S, AMMASSARI A, MENZAGHI B, DE SOCIO GV, FRANZETTI M, SORIA A, MESCHIARI M, SASSET L, PELLICANÒ G, MAZZOTTA E, TREZZI M, CELESIA BM, MELZI S, CARENZI L, RICCI E, RIZZARDINI G. Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E Study. Int J Antimicrob Agents 2014; 43: 189-194. doi: 10.1016/j.ijantimicag.2013.10.013
7. CELESIA BM, NIGRO L, PINZONE MR, COCO C, LA ROSA R, BISICCHIA F, MAVILLA S, GUSSIO M, PELLICANÒ G, MILIONI V, PALERMO F, RUSSO R, MUGHINI MT, MARTELLOTTA F, TAIBI R, CACOPARDO B, NUNNARI G. High prevalence of undiagnosed anxiety symptoms among HIV-positive individuals on cART: a cross-sectional study. Eur Rev Med Pharmacol Sci 2013; 17: 2040-2046.
8. SCARPINO M, SANTORO M, PELLICANÒ GF. HIV infection and kidney disease: literature review. Infect Dis Trop Med 2015; 1:e195.
9. VISALLI G, PAIARDINI M, CHIRICO C, CERVASI B, CURRÒ M, FERLAZZO N, BERTUCCIO MP, FAVALORO A, PELLICANÒ G, STURNIOLO G, SPATARO P, IENTILE R, PICERNO I, PIEDIMONTE G. Intracellular accumulation of cell cycle regulatory proteins and nucleolin re-localization are associated with pre-lethal ultrastructural lesions in circulating T lymphocytes: the HIV-induced cell cycle dysregulation revisited. Cell Cycle 2010; 9: 2130-2140. doi: 10.4161/cc.9.11.11754
10. SQUILLACE N, RICCI E, QUIRINO T, GORI A, BANDERA A, CARENZI L, DE SOCIO GV, OROFINO G, MARTINELLI C, MADEDDU G, RUSCONI S, MAGGI P, CELESIA BM, CORDIER L, VICHI F, CALZA L, FALASCA K, DI BIAGIO A, PELLICANÒ GF, BONFANTI P, CISAI STUDY GROUP. Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project. PLoS One 2017; 12: e0179254. doi: 10.1371/journal.pone.0179254
11. TROVATO M, RUGGERI RM, SCIACCHITANO S, VICCHIO TM, PICERNO I, PELLICANÒ G, VALENTI A, VISALLI G. Serum interleukin-6 levels are increased in HIV-infected patients that develop autoimmune disease during long-term follow-up. Immunobiology 2018; 223: 264-268. doi: 10.1016/j.imbio.2017.10.039. Epub 2017 Oct 16.
12. CELESIA BM, SOFIA SA, RAPISARDA L, MARESCA M, VINCI L. Anxiety, depression and sleep disturbances in HIV+ patients chronically treated with an efavirenz-based regimen. Infect Dis Trop Med 2017; 3: e394.
13. CAPELLI A, LANDONIO S, MERAVIGLIA P, DI BIAGIO A, CAPUTO LO S, STERRANTINO G, AMMASSARI A, MENZAGHI B, FRANZETTI M, DE SOCIO GV, PELLICANÒ G, MAZZOTTA E, SORIA A, MESCHIARI M, TREZZI M, SASSET L, CELESIA BM, ZUCCHI P, MELZI S, RICCI E, RIZZARDINI G. 96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience. PLoS One 2012; 7: e39222. doi: 10.1371/journal.pone.0039222
14. BERRETTA M, MARTELLOTTA F, DI FRANZIA R, SPINA M, VACCHER E, BALESTRERI L, BORSATTI E, BEARZ A, DE PAOLI P, TIRELLI U. Clinical presentation and outcome of non-

- AIDS defining cancers, in HIV-infected patients in the ART-era: the Italian Cooperative Group on AIDS and tumors activity. *Eur Rev Med Pharmacol Sci* 2015; 19: 3619-3634.
15. PINZONE MR, NUNNARI G. Prevalence of comorbidities in a cohort of women living with HIV. *Infect Dis Trop Med* 2015; 1: e165.
 16. FONTANA DEL VECCHIO R, PINZONE MR, CACOPARDO B, NUNNARI G. Anal cancer in HIV-positive patients. *WCRJ* 2014; 1: e405.
 17. PINZONE MR, CACOPARDO B, CONDORELLI F, ROSA MD, NUNNARI G. Sirtuin-1 and HIV-1: an overview. *Current Drug Targets* 2013; 14: 648-652. doi: 10.2174/1389450111314060005
 18. CASTRONUOVO D, CACOPARDO B, PINZONE MR, DI ROSA M, MARTELOTTA F, SCHIOPPA O, MORENO S, NUNNARI G. Bone disease in the setting of HIV infection: update and review of the literature. *Eur Rev Med Pharmacol Sci* 2013; 17: 2413-2419.
 19. BAGELLA P, FIORE V, CARUANA G, MADEDDU G. Editorial - Non AIDS-defining malignancies: a new epidemic in HIV-infected population for the upcoming decades? *Eur Rev Med Pharmacol Sci* 2017; 21: 4744-4745.
 20. LAI V, FIORE V, CALIA GM, LOVIGU C, ZIZZI B, BUDRONI C, PERUZZU F, BAGELLA P, MURA MS. Relationship between neurocognitive impairment and cardiovascular risk in an HIV-infected patient: a case report. *Infect Dis Trop Med* 2015; 1: e182.
 21. FACCIOLÀ A, VENANZI RULLO E, CECCARELLI M, D'ALEO F, DI ROSA M, PINZONE MR, CONDORELLI F, VISALLI G, PICERNO I, FISICHELLA R, NUNNARI G, PELLICANÒ GF. Kaposi's sarcoma in HIV-infected patients in the era of new antiretrovirals. *Eur Rev Med Pharmacol Sci* 2017; 21: 5868-5869. doi: 10.26355/eurrev_201712_14036
 22. D'ALEO F, CECCARELLI M, VENANZI RULLO E, FACCIOLÀ A, DI ROSA M, PINZONE MR, CONDORELLI F, VISALLI G, PICERNO I, BERRETTA M, PELLICANÒ GF, NUNNARI G. Hepatitis C-related hepatocellular carcinoma: diagnostic and therapeutic management in HIV-patients. *Eur Rev Med Pharmacol Sci* 2017; 21: 5859-5867.
 23. DOMBLIDES C, CANELLAS A, WISLEZ M, FALLET V, ANTOINE M, CREQUIT P, CADRANEL J, LAVOLE A. Le cancer bronchopulmonaire chez les patients infectés par le VIH. *Bull Cancer* 2018; 105: 111-119. doi: 10.1016/j.bulcan.2017.11.002
 24. PAKKALA S, RAMALINGAM SS. Lung Cancer in HIV-Positive Patients. *J Thorac Oncol* 2010; 5: 1864-1871. doi: 10.1097/JTO.0b013e3181f387fd
 25. PINZONE MR, FIORICA F, DI ROSA M, MALAGUARNERA G, MALAGUARNERA L, CACOPARDO B, ZANGHI G, NUNNARI G. Non-AIDS-defining cancers among HIV-infected people. *Eur Rev Med Pharmacol Sci* 2012; 16: 1377-1388.
 26. PARKIN DM. The global health burden of infection-associated cancers in the year 2002. *Int J Cancer* 2006; 118: 3030-3044. doi: 10.1002/ijc.21731
 27. AKHTAR N, BANSAL JG. Risk factors of lung cancer in nonsmoker. *Curr Probl Cancer* 2017; 41: 328-339. doi: 10.1016/j.currproblcancer.2017.07.002
 28. SHIELS MS, ENGELS EA. Evolving epidemiology of HIV-associated malignancies. *Current Opinion in HIV and AIDS* 2017; 12: 6-11. doi: 10.1097/COH.0000000000000327
 29. HALL EC, PFEIFFER RM, SEGEV DL, ENGELS EA. Cumulative incidence of cancer after solid organ transplantation. *Cancer* 2013; 119: 2300-2308. doi: 10.1002/cncr.28043
 30. COGHILL AE, SHIELS MS, SUNEJA G, ENGELS EA. Elevated cancer-specific mortality among HIV-infected patients in the United States. *J Clin Oncol* 2015; 33: 2376-2383. doi: 10.1200/JCO.2014.59.5967
 31. GRANDE E, ZUCCHETTO A, SULIGOI B, GRIPPO F, PAPPAGALLO M, VIRDONE S, CAMONI L, TABORELLI M, REGINE V, SERRAINO D, FROVA L. Multiple cause-of-death data among people with AIDS in Italy: a nationwide cross-sectional study. *Popul Health Metr* 2017; 15: 19. doi: 10.1186/s12963-017-0135-3
 32. ZUCCHETTO A, VIRDONE S, TABORELLI M, GRANDE E, CAMONI L, PAPPAGALLO M, REGINE V, GRIPPO F, POLESEL J, DAL MASO L, SULIGOI B, FROVA L, SERRAINO D. Non-AIDS-defining cancer mortality: emerging patterns in the late HAART Era. *J Acquir Immune Defic Syndr* 2016; 73: 190-196. doi: 10.1097/QAI.0000000000001033
 33. SULIGOI B, ZUCCHETTO A, GRANDE E, CAMONI L, DAL MASO L, FROVA L, VIRDONE S, BOROS S, PAPPAGALLO M, TABORELLI M, REGINE V, DE PAOLI P, SERRAINO D. Risk factors for early mortality after AIDS in the cART era: a population-based cohort study in Italy. *BMC Infect Dis* 2015; 15: 229. doi: 10.1186/s12879-015-0960-6
 34. MASO LD, SULIGOI B, FRANCESCHI S, BRAGA C, BUZZONI C, POLESEL J, ZUCCHETTO A, PISELLI P, FALCINI F, CALDARELLA A, ZANETTI R, VERCELLI M, GUZZINATI S, RUSSO A, TAGLIABUE G, IACHETTA F, FERRETTI S, LIMINA RM, MANGONE L, MICHIRARA M, STRACCI F, PIRINO DR, PIFFER S, GIACOMIN A, VITARELLI S, MAZZOLENI G, IANNELLI A, CONTRINO ML, FUSCO M, TUMINO R, FANETTI AC, DE PAOLI P, DECARLI A, SERRAINO D. Survival after cancer in Italian persons with AIDS, 1986-2005: a population-based estimation. *J Acquir Immune Defic Syndr* 2014; 66: 428-435. doi: 10.1097/QAI.0000000000000184
 35. SPANO JP, MASSIANI MA, BENTATA M, RIXE O, FRIARD S, BOSSI P, ROUGES F, KATLAMA C, BREAU JL, MORERE JF, KHAYAT D, COUDERC LJ. Lung cancer in patients with HIV infection and review of the literature. *Medical Oncology* 2004; 21: 109-115. doi: 10.1385/MO:21:2:109
 36. PACEK LR, CIOE PA. tobacco use, use disorders, and smoking cessation interventions in persons living with HIV. *Curr HIV/AIDS Rep* 2015; 12: 413-420. doi: 10.1007/s11904-015-0281-9
 37. PROBST C, SIMBAYI LC, PARRY CDH, SHUPER PA, REHM J. Alcohol use, socioeconomic status and risk of HIV infections. *AIDS Behav* 2017; 21: 1926-1937. doi: 10.1007/s10461-017-1758-x
 38. BONNET F, BURTY C, LEWDEN C, COSTAGLIOLA D, MAY T, BOUTELOUP V, ROSENTHAL E, JOUGLA E, CACOUB P, SALMON D, CHENE G, MORLAT P, HEPATITES ANRS. Changes in cancer mortality among HIV-infected patients: the mortality 2005 survey. *Clin Infect Dis* 2009; 48: 633-639. doi: 10.1086/596766
 39. BROCK MV, HOOKER CM, ENGELS EA, MOORE RD, GILLISON ML, ALBERG AJ, KERULY JC, YANG SC, HEITMILLER RF, BAYLIN SB, HERMAN JG, BRAHMER JR. Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care. *J Acquir Immune Defic Syndr* 2006; 43: 47-55. doi: 10.1097/01.qai.0000232260.95288.93
 40. SOCIETÀ ITALIANA DI MALATTIE INFETTIVE E TROPICALI. Linee Guida Italiane sull'utilizzo della Terapia Antiretrovirale e la gestione diagnostico-clinica delle persone con infezione da HIV-1. http://www.salute.gov.it/imgs/C_17_pubblicazioni_2696_allegato.pdf Accessed 23 February 2018
 41. SHEBL FM, ENGELS EA, GOEDERT JJ, CHATURVEDI AK. Pulmonary infections and risk of lung cancer among persons with AIDS. *J Acquir Immune Defic Syndr* 2010; 55: 375-379. doi: 10.1097/QAI.0b013e3181eef4f7
 42. SIGEL K, MAKINSON A, THALER J. Lung cancer in persons with HIV. *Curr Opin HIV AIDS* 2017; 12: 31-38. doi: 10.1097/COH.0000000000000326



43. DRUMMOND MB, KIRK GD. HIV-associated obstructive lung diseases: insights and implications for the clinician. *Lancet Respir Med* 2014; 2: 583-592. doi: 10.1016/S2213-2600(14)70017-7
44. CROTHERS K, MCGINNIS K, KLEERUP E, WONGTRAKOOL C, HOO GS, KIM J, SHARAFKHANEH A, HUANG L, LUO Z, THOMPSON B, DIAZ P, KIRK GD, ROM W, DETELS R, KINGSLEY L, MORRIS A. HIV infection is associated with reduced pulmonary diffusing capacity. *J Acquir Immune Defic Syndr* 2013; 64: 271-278. doi: 10.1097/QAI.0b013e3182a9215a
45. HLEYHEL M, BOUVIER AM, BELOT A, TATTEVIN P, PACANOWSKI J, GENET P, DE CASTRO N, BERGER JL, DUPONT C, LAVOLE A, PRADIER C, SALMON D, SIMON A, MARTINEZ V, SPANO JP, COSTAGLIOLA D, GRABAR S, Cancer Risk Group of the French Hospital Database on HIV (FHDH-ANRS CO4). Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort. *AIDS* 2014; 28:2109-2118. doi: 10.1097/QAD.0000000000000382
46. BORGES AH, SILVERBERG MJ, WENTWORTH D, GRULICH AE, FÄTKENHEUER G, MITSUYASU R, TAMBUSI G, SABIN CA, NEATON JD, LUNDGREN JD, INSIGHT SMART, ESPRIT, SILCAAT STUDY GROUPS. Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers. *AIDS* 2013; 27: 1433-1441. doi: 10.1097/QAD.0b013e32835f6b0c
47. CRIBBS SK, LENNOX J, CALIENDO AM, BROWN LA, GUIDOT DM. Healthy HIV-1-infected individuals on highly active antiretroviral therapy harbor HIV-1 in their alveolar macrophages. *AIDS Res Hum Retroviruses* 2015; 31: 64-70. doi: 10.1089/AID.2014.0133
48. MATSUMOTO Y, OHARA S, FURUKAWA R, USUI K. The prognosis of small cell lung cancer in patients with pulmonary fibrosis. *Anticancer Res* 2017; 37: 5791-5795. doi: 10.21873/anticancer.12021
49. LEDUC C, ANTONI D, CHARLOUX A, FALCOZ PE, QUOIX E. Comorbidities in the management of patients with lung cancer. *Eur Respir J* 2017; 49: 1601721. doi: 10.1183/13993003.01721-2016
50. CHIU CG, SMITH D, SALTERS KA, ZHANG W, KANTERS S, MILAN D, MONTANER JSG, COLDMAN A, HOGG RS, WISEMAN SM. Overview of cancer incidence and mortality among people living with HIV/AIDS in British Columbia, Canada: implications for HAART use and NADM development. *BMC Cancer* 2017; 17: 270. doi: 10.1186/s12885-017-3229-1
51. BRICKMAN C, PALEFSKY JM. Cancer in the HIV-infected host: epidemiology and pathogenesis in the antiretroviral era. *Curr HIV/AIDS Rep* 2015; 12: 388-396. doi: 10.1007/s11904-015-0283-7
52. PALACIOS R, PASCUAL J, CABRERA E, LEBRON JM, GUERRERO-LEON MA, DEL ARCO A, COLMENERO JD, SANTOS J. Lung cancer in HIV-infected patients. *Int J STD AIDS* 2014; 25: 239-243. doi: 10.1177/0956462413499317
53. BEARZ A, VACCHER E, MARTELOTTA F, SPINA M, TALAMINI R, LLESHI A, CACOPARDO B, NUNNARI G, BERRETTA M, TIRELLI U. Lung cancer in HIV positive patients: the GICAT experience. *Eur Rev Med Pharmacol Sci* 2014; 18: 500-508.
54. ABOULAFIA DM. Cancer screening in women living with HIV infection. *Womens Health (Lond)* 2017; 13: 68-79. doi: 10.1177/1745505717731970
55. MENA A, MEIJIDE H, MARCOS PJ. Lung cancer in HIV-infected patients. *AIDS Rev* 2016; 18: 138-144.
56. COLLINI P, MORRIS A. Maintaining lung health with longstanding HIV. *Curr Opin Infect Dis* 2016; 29: 31-38. doi: 10.1097/QCO.0000000000000221
57. EUROPEAN AIDS CLINICAL SOCIETY. EACS GUIDELINES - Version 9.0 October 2017. 1-102. http://www.eacso-society.org/files/guidelines_9.0-english.pdf Accessed 23 February 2018
58. WANG S, LI M, CHEN H, LI J, ZENG Q. FDG PET/CT in hepatoid adenocarcinoma of the lung. *Clin Nucl Med* 2016; 41: e340-e341. doi: 10.1097/RLU.0000000000001231
59. COUNTS SJ, KIM AW. Diagnostic imaging and newer modalities for thoracic diseases PET/computed tomographic imaging and endobronchial ultrasound for staging and its implication for lung cancer. *PET Clin* 2018; 13: 113-126. doi: 10.1016/j.cpet.2017.09.003
60. DELBEKE D, MARTIN WH, SANDLER MP, CHAPMAN WC, WRIGHT JK, PINSON CW. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. *Arch Surg* 1998; 133: 510-515. doi: 10.1001/archsurg.133.5.510
61. DENNIE C, THORNHILL R, SOUZA CA, ODONKOR C, PANTAROTTO JR, MACRAE R, COOK G. Quantitative texture analysis on pre-treatment computed tomography predicts local recurrence in stage I non-small cell lung cancer following stereotactic radiation therapy. *Quant Imaging Med Surg* 2017; 7: 614-622.
62. PITCHER RD, BENINGFIELD SJ, ZAR HJ. The chest X-ray features of chronic respiratory disease in HIV-infected children--a review. *Paediatr Respir Rev* 2015; 16: 258-266. doi: 10.1016/j.prrv.2015.01.005
63. LODES C, SCHAAL M, LABANI A, JEUNG MY, ROY C, OHANA M. Scanner thoracique ultra-basse dose: la mort de la radiographie thoracique? *Presse Med* 2016; 45: 291-301. doi: 10.1016/j.lpm.2015.12.003
64. ELLIS S, AZIZ Z. Radiology as an aid to diagnosis in lung disease. *Postgrad Med J* 2016; 92: 620-623. doi: 10.1136/postgradmedj-2015-133825
65. HERTH FJ, EBERHARDT R, SCHUHMANN M. Bronchoscopy in lung cancer: navigational modalities and their clinical use. *Expert Rev Respir Med* 2016; 10: 901-906. doi: 10.1080/17476348.2016.1191354
66. VAN BEEK EJ, MIRSAADRAE S, MURCHISON JT. Lung cancer screening: computed tomography or chest radiographs? *World J Radiol* 2015; 7: 189-193. doi: 10.4329/wjr.v7.i8.189
67. TALLEY TA. Early detection of lung cancer using low-dose computed tomography. *Radiol Technol* 2017; 89: 206-209.
68. JEMAL A, BRAY F, CENTER, MELISSA M, FERLAY J, WARD E, FORMAN D. Global cancer statistics. *CA Cancer J Clin* 2011; 61: 69-90. doi: 10.3322/caac.20107
69. SILVERBERG MJ, LAU B, ACHENBACH CJ, JING Y, ALTHOFF KN, D'SOUZA G, ENGELS EA, HESSOL NA, BROOKS JT, BURCHELL AN, GILL MJ, GOEDERT JJ, HOGG R, HORBERG MA, KIRK GD, KITAHATA MM, KORTHUIS PT, MATHEWS WC, MAYOR A, MODUR SP, NAPRAVNIK S, NOVAK RM, PATEL P, RACHLIS AR, STERLING TR, WILLIG JH, JUSTICE AC, MOORE RD, DUBROW R, NORTH AMERICAN AIDS COHORT COLLABORATION ON RESEARCH AND DESIGN OF THE INTERNATIONAL EPIDEMIOLOGIC DATABASES TO EVALUATE AIDS. Cumulative incidence of cancer among persons with HIV in North America: a cohort study. *Ann Int Med* 2015; 163: 507-518. doi: 10.7326/M14-2768
70. WANG SY, L YI, JIANG YS, LI RZ. Investigation of serum miR-411 as a diagnosis and prognosis biomarker for non-small cell lung cancer. *Eur Rev Med Pharmacol Sci* 2017; 21: 4092-4097.
71. ZHAO Z, QIN L, LI S. miR-411 contributes the cell proliferation of lung cancer by targeting FOXO1. *Tumour Biol* 2016; 37: 5551-5560. doi: 10.1007/s13277-015-4425-8
72. LI N, FENG XB, TAN Q, LUO P, JING W, ZHU M, LIANG C, TU J, NING Y. Identification of circulating long noncoding RNA linc00152 as a novel biomarker for diagnosis and monitoring of non-small-cell lung cancer. *Dis Markers* 2017; 2017: 7439698-8. doi: 10.1155/2017/7439698
73. ZHANG PP, WANG YQ, WENG WW, NIE W, WU Y, DENG Y, WEI P, XU MD, WANG CF. Linc00152 promotes can-

- cer cell proliferation and invasion and predicts poor prognosis in lung adenocarcinoma. *J Cancer* 2017; 8: 2042-2050. doi: 10.7150/jca.18852
74. FENG S, ZHANG J, SU W, BAI S, XIAO L, CHEN X, LIN J, REDDY RM, CHANG AC, BEER DG, CHEN G. Overexpression of LINC00152 correlates with poor patient survival and knockdown impairs cell proliferation in lung cancer. *Sci Rep* 2017; 7: 2982. doi: 10.1038/s41598-017-03043-x
 75. CHEN QN, CHEN X, CHEN ZY, NIE FQ, WEI CC, MA HW, WAN L, YAN S, REN SN, WANG ZX. Long intergenic non-coding RNA 00152 promotes lung adenocarcinoma proliferation via interacting with EZH2 and repressing IL24 expression. *Mol Cancer* 2017; 16: 17. doi: 10.1186/s12943-017-0581-3
 76. MIYATA T, OYAMA T, YOSHIMATSU T, HIGA H, KAWANO D, SEKIMURA A, YAMASHITA N, SO T, GOTOH A. The clinical significance of cancer stem cell markers ALDH1A1 and CD133 in lung adenocarcinoma. *Anticancer Res* 2017; 37: 2541-2547. doi: 10.21873/anticancer.11597
 77. YU J, ALHARBI A, SHAN H, HAO Y, SNETSINGER B, RAUH MJ, YANG X. TAZ induces lung cancer stem cell properties and tumorigenesis by up-regulating ALDH1A1. *Oncotarget* 2017; 8: 38426-38443. doi: 10.18632/oncotarget.16430
 78. ZHOU Y, WANG Y, JU X, LAN J, ZOU H, LI S, QI Y, JIA W, HU J, LIANG W, ZHANG W, PANG L, LI F. Clinicopathological significance of ALDH1A1 in lung, colorectal, and breast cancers: a meta-analysis. *Biomark Med* 2015; 9: 777-790. doi: 10.2217/BMM.15.49
 79. GAO F, ZHOU B, XU JC, GAO X, LI SX, ZHU GC, ZHANG XG, YANG C. The role of LGR5 and ALDH1A1 in non-small cell lung cancer: cancer progression and prognosis. *Biochem Biophys Res Commun* 2015; 462: 91-98. doi: 10.1016/j.bbrc.2015.04.029
 80. CAO YT, LI JH, WANG YT, FU YW, XU J. Serum ALDH1A1 is a tumor marker for the diagnosis of non-small cell lung cancer. *Tumori* 2014; 100: 214-218. doi: 10.1700/1491.16419
 81. OSMANI L, ASKIN F, GABRIELSON E, LI QK. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy. *Semin Cancer Biol*. 2017 Nov 26. pii: S1044-579X(17)30097-4. doi: 10.1016/j.semcancer.2017.11.019. [Epub ahead of print]
 82. ALBERG AJ, BROCK MV, FORD JG, SAMET JM, SPIVACK SD. Epidemiology of lung cancer diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2013; 143: e1S-e29S. doi: 10.1378/chest.12-2345
 83. SEITZ HK, STICKEL F. Molecular mechanisms of alcohol-mediated carcinogenesis. *Nat rev Canc* 2007; 7: 599-612. doi: 10.1038/nrc2191
 84. YANG Y, SUN J, CHEN T, TAO Z, ZHANG X, TIAN F, ZHOU X, LU D. Tat-interactive Protein-60KDA (TIP60) regulates the tumorigenesis of lung cancer in vitro. *J Cancer* 2017; 8: 2277-2281. doi: 10.7150/jca.19677
 85. MEIJIDE H, MENA A, MARCOS PJ, RODRIGUEZ-OSORIO I, SUAREZ-FUENTETAJA R, CASTRO A, POVEDA E, PEDREIRA JD. Lung cancer in patients living with HIV infection. *AIDS* 2015; 29: 2363-2364. doi: 10.1097/QAD.0000000000000840
 86. VANDENHENDE MA, ROUSSILLON C, HENARD S, MORLAT P, OKSENHENDLER E, AUMAITRE H, GEORGET A, MAY T, ROSENTHAL E, SALMON D, CACOUB P, COSTAGLIOLA D, CHENE G, BONNET F, GRP AEM2S. Cancer-related causes of death among HIV-infected patients in France in 2010: evolution since 2000. *PLoS One* 2015. doi: 10.1371/journal.pone.0129550
 87. MLIKA M, HELAL I, BRAHAM E, AYADI A, MRABET A, MEZNI F. The 2015 classification of lung adenocarcinomas: reproducibility in a Tunisian department specialised in thoracic pathology. *Ann Pathol* 2017; 37: 467-471. doi: 10.1016/j.annpat.2017.09.002
 88. INAMURA K. Lung cancer: understanding its molecular pathology and the 2015 WHO classification. *Front Oncol* 2017; 7: 193. doi: 10.3389/fonc.2017.00193
 89. CHEN R, DING Z, ZHU L, LU S, YU Y. Correlation of clinicopathologic features and lung squamous cell carcinoma subtypes according to the 2015 WHO classification. *Eur J Surg Oncol* 2017; 43: 2308-2314. doi: 10.1016/j.ejso.2017.09.011
 90. RAMI-PORTA R, BALL D, CROWLEY J, GIROUX DJ, JETT J, TRAVIS WD, TSUBOI M, VALLIERES E, GOLDSTRAW P. The IASLC lung cancer staging project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. *J Thorac Oncol* 2007; 2: 593-602. doi: 10.1097/JTO.0b013e31807a2f81
 91. DETTERBECK FC. The eighth edition TNM stage classification for lung cancer: what does it mean on main street? *J Thorac Cardiovasc Surg* 2018; 155: 356-359. doi: 10.1016/j.jtcvs.2017.08.138
 92. TOMIZAWA K, SHIMIZU S, OHARA S, FUJINO T, NISHINO M, SESUMI Y, KOBAYASHI Y, SATO K, CHIBA M, SHIMOJI M, SUDA K, TAKEMOTO T, MITSUDOMI T. Clinical significance of tumor cavitation in surgically resected early-stage primary lung cancer. *Lung Cancer* 2017; 112: 57-61. doi: 10.1016/j.lungcan.2017.08.004
 93. CATTONI M, VALLIERES E, BROWN LM, SARKESHK AA, MARGARITORA S, SICILIANI A, FILOSSO PL, GUERRERA F, IMPERATORI A, ROTOLO N, FARJAH F, WANDELL G, COSTAS K, MANN C, HUBKA M, KAPLAN S, FARIVAR AS, AYE RW, LOUIE BE. Improvement in TNM staging of pulmonary neuroendocrine tumors requires histology and regrouping of tumor size. *J Thorac Cardiovasc Surg* 2018; 155: 405-413. doi: 10.1016/j.jtcvs.2017.08.102
 94. LEE JY, MOORE PC, STELIGA MA. Do HIV-infected non-small cell lung cancer patients receive guidance-concordant care? *Med Care* 2013; 51: 1063-1068. doi: 10.1097/MLR.0000000000000003
 95. ZHAO J, JIANG D, LIU R, LI X. [A report of lung adenocarcinoma with HIV carrier and the literature review]. *Zhongguo Fei Ai Za Zhi* 2013; 16: 114-116. doi: 10.3779/j.issn.1009-3419.2013.02.10
 96. FITZPATRICK M, BROOKS JT, KAPLAN JE. Epidemiology of HIV-associated lung disease in the United States. *Semin Respir Crit Care Med* 2016; 37: 181-198. doi: 10.1055/s-0036-1572556
 97. HESSOL NA, MARTINEZ-MAZA O, LEVINE AM, MORRIS A, MARGOLICK JB, COHEN MH, JACOBSON LP, SEABERG EC. Lung cancer incidence and survival among HIV-infected and uninfected women and men. *AIDS* 2015; 29: 1183-1193. doi: 10.1097/QAD.0000000000000690
 98. LACKEY A, DONINGTON JS. Surgical management of lung cancer. *Semin Intervent Radiol* 2013; 30: 133-140.
 99. PASSLICK B. Initial surgical staging of lung cancer. *Lung Cancer* 2003; 42: S21-S25. doi: 10.1016/S0169-5002(03)00301-5
 100. DARLING GE, ALLEN MS, DECKER PA, BALLMAN K, MALTHANER RA, INCULET RI, JONES DR, MCKENNA RJ, LANDRENEAU RJ, RUSCH VW, PUTNAM JBJ. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. *J Thorac Cardiovasc Surg* 2011; 141: 662-670. doi: 10.1016/j.jtcvs.2010.11.008



101. GINSBERG RJ, RUBINSTEIN LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung cancer study group. *Ann Thorac Surg* 1995; 60: 615-622.
102. TIEU BH, SANBORN RE, THOMAS CR. Neoadjuvant therapy for resectable non-small cell lung cancer with mediastinal lymph node involvement. *Thorac Surg Clin* 2008; 18: 403-415. doi: 10.1016/j.thorsurg.2008.07.004
103. TAZZA M, METRO G. Adjuvant treatment of non-small cell lung cancer: focus on targeted therapy. *J Thorac Dis* 2017; 9: 4064-4069. doi: 10.21037/jtd.2017.08.130
104. KAZAZ SN, OZTOP I. Treatment after first-generation epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer. *Turk Thorac J* 2017; 18: 66-71.
105. GHAFOR Q, BAIJAL S, TANIÈRE P, O'SULLIVAN B, EVANS M, MIDDLETON G. Epidermal Growth Factor Receptor (EGFR) kinase inhibitors and Non-Small Cell Lung Cancer (NSCLC) - advances in molecular diagnostic techniques to facilitate targeted therapy. *Pathol Oncol Res* 2017; 24: 1-9. doi: 10.1007/s12253-017-0377-1
106. VAVALA T. Role of afatinib in the treatment of advanced lung squamous cell carcinoma. *Clin Pharmacol* 2017; 9: 147-157.
107. MEZQUITA L, PLANCHARD D. The role of brigatinib in crizotinib-resistant non-small cell lung cancer. *Cancer Manag Res* 2018; 10: 123-130.
108. OBEID JM, ERDAG G, SMOLKIN ME, DEACON DH, PATTERSON JW, CHEN L, BULLOCK TN, SLINGLUFF CL. PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: correlation with tumor-infiltrating immune cells and clinical outcome. *Oncoimmunology* 2016; 5: e1235107.
109. BLACKBURN SD, SHIN H, HAINING WN, ZOU T, WORKMAN CJ, POLLEY A, BETTS MR, FREEMAN GJ, VIGNALI DAA, WHERRY EJ. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. *Nat Immunol* 2009; 10: 29-37. doi: 10.1038/ni.1679
110. HOFFMANN M, PANTAZIS N, MARTIN GE, HICKLING S, HURST J, MEYEROWITZ J, WILLBERG CB, ROBINSON N, BROWN H, FISHER M, KINLOCH S, BABIKER A, WEBER J, NWOKOLO N, FOX J, FIDLER S, PHILLIPS R, FRATER J, INVESTIGATORS S, INVESTIGATORS C. Exhaustion of activated CD8 T cells predicts disease progression in primary HIV-1 infection. *PLoS Pathog* 2016; 12: e1005661. doi: 10.1371/journal.ppat.1005661. eCollection 2016 Jul.
111. MARRA A, FERRONE C, FUSCIELLO C, SCOGNAMIGLIO G, FERRONE S, PEPE S, PERRI F, SABBATINO F. Translational research in cutaneous melanoma: new therapeutic perspectives. *Anticancer Agents Med Chem* 2017; 18: 1-16. doi: 10.2174/1871520618666171219115335
112. AMERICAN ASSOCIATION FOR CANCER RESEARCH. Anti-PD-1 therapy OK for most with HIV. *Cancer Discov* 2018; 8: 130-131. doi: 10.1158/2159-8290.CD-NB2017-174